{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:08:03Z","timestamp":1790197683441,"version":"4.1.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1698","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved RiVive (Harm Reduction Therapeutics), a 3-mg naloxone nasal spray, as an over-the-counter (OTC) product for emergency treatment of opioid overdose.1 Two 4-mg naloxone nasal spray formulations, Narcan and one of its generics, were approved for OTC sale in 2023.<\/jats:p>","DOI":"10.58347\/tml.2024.1698d","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:56:24Z","timestamp":1711047384000},"page":"47-48","source":"Crossref","is-referenced-by-count":1,"title":["In Brief: A New OTC Naloxone Nasal Spray (RiVive)"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"37151","published-online":{"date-parts":[[2024,3,18]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:56:45Z","timestamp":1711047405000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1698d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":0,"journal-issue":{"issue":"1698","published-online":{"date-parts":[[2024,3,18]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1698d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}